AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, which spun out of Pfizer ...
Subscribe to TheStreet's free daily newsletter 💰💵 That is why the market saw AbbVie make a number of acquisitions to expand ...
13don MSN
Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.
AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.
Let's decide whether AbbVie is a buy. In the pharmaceutical business ... and $8.7 billion for Cerevel Therapeutics. The company's ratio of debt to EBITDA (earnings before interest, taxes ...
Let's decide whether AbbVie is a buy. In the pharmaceutical business ... and $8.7 billion for Cerevel Therapeutics.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback